At the same time, targeting Eg5 could represent an approach to overcome GBM resistance to current standard of care: e.g., bevacizumab is an anti-VEGF antibody currently used in recurrent GBM, although resistance phenomena are responsible for a reduction of efficacy. The gene discussed is KIF11; the disease is glioblastoma.